Search results
Results from the WOW.Com Content Network
Increase in systemic exposure is proportional over the dose range of 50–400 mg. No time-dependent change in kinetics was observed through 12 weeks of dosing. Apparent steady state for armodafinil was reached within 7 days of dosing. At steady state, the systemic exposure for armodafinil is 1.8 times the exposure observed after a single dose.
A eugeroic, or eugregoric, also known as a vigilance-promoting agent, is a type of drug that increases vigilance (that is, alertness and/or wakefulness). [1] [2] [3 ...
Presbycusis is the most common cause of hearing loss, affecting one out of three persons by age 65, and one out of two by age 75. Presbycusis is the second most common illness next to arthritis in aged people.
Solriamfetol is used to promote wakefulness in the treatment of excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea in adults. [1] It appears to be more effective in improving excessive daytime sleepiness associated with obstructive sleep apnea than certain other wakefulness-promoting agents including modafinil, armodafinil, and pitolisant.
Common side effects of Modafinil include anxiety, insomnia, dizziness, and headache. Modafinil has potential for causing severe allergic reactions, psychiatric effects, [3] hypersensitivity, adverse interactions with prescription drugs, and misuse or abuse. [3] [8] [15] Modafinil may harm the fetus if taken during or two months prior to ...
Neuromonics is a patented treatment for tinnitus that combines acoustic stimulation with cognitive-behavioural therapy to provide relief for people suffering from tinnitus. The treatment aims to retrain the brain to filter out the sounds of tinnitus, making them less noticeable and bothersome.
Eperisone hydrochloride is available as the brand name preparations Myonal and Epry as 50 mg sugar-coated tablets, or as 10% granules for oral administration. [6] An experimental form of the drug, as a transdermal patch system, has shown promising results in laboratory tests on rodents; however, this product is not currently available for human use.
Cinnarizine is predominantly used to treat nausea and vomiting associated with motion sickness, [6] vertigo, [8] Ménière's disease, [9] or Cogan's syndrome. [3] It is one of only a few drugs that has a beneficial effect in the chronic treatment of the vertigo and tinnitus associated with Ménière's disease.